The substantia nigra (SN) is among the most severely affected structures in Progressive Supranuclear Palsy (PSP), a 4-repeat (4R) tauopathy characterised by globose neurofibrillary tangles, neuronal loss, and gliosis across brainstem and basal ganglia nuclei[1]. Within the SN, the dopaminergic neurons of the pars compacta (SNc) undergo 60-80% cell loss, while the GABAergic projection neurons of the pars reticulata (SNr) — the major output relay of the basal ganglia — also degenerate substantially[2]. This dual-compartment devastation distinguishes PSP from Parkinson's disease (PD), where SNc loss is severe but SNr is largely spared[3]. The resulting nigrostriatal dopamine deficit produces the akinetic-rigid parkinsonism of PSP, while SNr dysfunction contributes to the hallmark vertical supranuclear gaze palsy and postural instability through disrupted inhibitory control of brainstem oculomotor and locomotor centres[4].
The SNc contains approximately 400,000-600,000 pigmented dopaminergic neurons per hemisphere in the healthy adult brain[5]. These neurons are identified by neuromelanin pigment and express tyrosine hydroxylase (TH), the rate-limiting enzyme for dopamine synthesis. SNc neurons project via the nigrostriatal pathway to the striatum, where they modulate the balance between the direct and indirect basal ganglia pathways. They fire tonically at 2-8 Hz and shift to phasic burst firing in response to reward prediction errors, providing a teaching signal for action selection[6].
The SNr is a GABAergic output nucleus of the basal ganglia, functionally analogous to the globus pallidus internus (GPi). SNr neurons fire tonically at 60-80 Hz, providing tonic inhibition of downstream targets including the superior colliculus (vertical and horizontal saccades), pedunculopontine nucleus (PPN) (locomotion), and ventrolateral thalamus (motor cortex activation)[7]. Disinhibition of these targets via striatal input is the mechanism by which voluntary movements and saccades are initiated.
PSP produces severe, relatively symmetric neuronal loss across both SN compartments[1:1][2:1]:
The SN harbours dense 4R tau pathology in PSP[1:2][10]:
Key hyperphosphorylation sites in PSP nigral tau include Ser202/Thr205 (AT8 epitope), Thr231 (TG3), Ser396/Ser404 (PHF-1), and Ser422[10:1]. GSK-3β and CDK5 are the primary kinases responsible, while PP2A phosphatase activity is reduced, shifting the equilibrium toward pathological hyperphosphorylation.
Several features of SNc dopaminergic neurons confer preferential vulnerability to tauopathy[5:1][13]:
The SN's extensive connectivity makes it a hub for prion-like tau spreading[17]:
Activated microglia and reactive astrocytes amplify neurodegeneration in the PSP substantia nigra[8:1][18]:
SNc dopaminergic loss produces the akinetic-rigid syndrome of PSP[9:1]:
SNr degeneration disinhibits the superior colliculus, disrupting saccadic eye movement control[4:2]:
| Feature | PSP | PD |
|---|---|---|
| SNc loss pattern | Dorsomedial (uniform) | Ventrolateral (selective) |
| SNr involvement | Severe (40-60% loss) | Minimal |
| Tau pathology | Globose NFTs (4R tau) | Absent (α-synuclein instead) |
| Levodopa response | Poor (20-30%) | Good (70-90%) |
| Symmetry | Bilateral from onset | Unilateral initially |
| Gaze palsy | Vertical supranuclear | Absent |
| Falls | Early (year 1) | Late (year 5+) |
Tau-targeted therapies aim to halt nigral degeneration:
Recent advances in understanding substantia nigra degeneration in PSP have revealed important insights:
Single-Cell Transcriptomics: Single-nucleus RNA sequencing of PSP substantia nigra has identified distinct neuronal subpopulations with differential vulnerability, including a resilient dopaminergic neuron cluster expressing higher levels of mitochondrial dynamics genes. [26]
Calcium Dysregulation: New studies demonstrate that Cav1.3 calcium channel hyperactivity in substantia nigra dopamine neurons drives oxidative stress and accelerates tau pathology propagation in PSP models. [27]
Alpha-Synuclein Interaction: Recent research reveals bidirectional interactions between tau and alpha-synuclein in the substantia nigra, with each protein accelerating the other's aggregation in a prion-like manner. [28]
Neuromelanin Imaging Advances: High-resolution neuromelanin-sensitive MRI sequences now allow earlier detection of substantia nigra degeneration in PSP, with automated segmentation algorithms improving diagnostic accuracy. [29]
Microglial Activation Patterns: TSPO-PET imaging shows distinct microglial activation patterns in PSP substantia nigra compared to PD, with more widespread inflammation correlating with faster disease progression. [30]
Therapeutic Targeting: New approaches targeting mitochondrial dysfunction (CoQ10 analogs, MitoQ), neuroinflammation (microglial modulation), and calcium homeostasis (isradipine) are in various stages of clinical development for PSP. [31]
Hauw JJ, Daniel SE, Dickson D, et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology. 1994. ↩︎ ↩︎ ↩︎
Hardman CD, Halliday GM, McRitchie DA, et al. Progressive supranuclear palsy affects both the substantia nigra pars compacta and reticulata. Exp Neurol. 1997. ↩︎ ↩︎
Jellinger KA. Neuropathology of progressive supranuclear palsy. J Neural Transm. 2001. ↩︎ ↩︎
Dickson DW, Ahmed Z, Algom AA, Tsuboi Y, Josephs KA. Neuropathology of variants of progressive supranuclear palsy. Curr Opin Neurol. 2010. ↩︎ ↩︎ ↩︎
Pakkenberg B, Møller A, Gundersen HJ, Mouritzen Dam A, Pakkenberg H. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. J Neurol Neurosurg Psychiatry. 1991. ↩︎ ↩︎
Schultz W. Dopamine reward prediction-error signalling: a two-component response. Nat Rev Neurosci. 2016. ↩︎
Hikosaka O, Takikawa Y, Kawagoe R. Role of the basal ganglia in the control of purposive saccadic eye movements. Physiol Rev. 2000. ↩︎
Fernández-Botrán R, Ahmed Z, Crespo FA, et al. Cytokine expression and microglial activation in progressive supranuclear palsy. Parkinsonism Relat Disord. 2011. ↩︎ ↩︎
Williams DR, de Silva R, Paviour DC, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain. 2005. ↩︎ ↩︎
Sergeant N, Wattez A, Delacourte A. Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: tau pathologies with exclusively "exon 10" isoforms. J Neurochem. 1999. ↩︎ ↩︎
Kovacs GG, Lukic MJ, Irwin DJ, et al. Distribution patterns of tau pathology in progressive supranuclear palsy. Acta Neuropathol. 2020. ↩︎
Shi Y, Zhang W, Yang Y, et al. Structure-based classification of tauopathies. Nature. 2021. ↩︎
Surmeier DJ, Obeso JA, Halliday GM. Selective neuronal vulnerability in Parkinson disease. Nat Rev Neurosci. 2017. ↩︎
Dexter DT, Carayon A, Javoy-Agid F, et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain. 1991. ↩︎
Myers AJ, Pittman AM, Zhao AS, et al. The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts. Neurobiol Dis. 2007. ↩︎
Albers DS, Swerdlow RH, Manfredi G, et al. Further evidence for mitochondrial dysfunction in progressive supranuclear palsy. Exp Neurol. 2001. ↩︎
Clavaguera F, Akatsu H, Fraser G, et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci USA. 2013. ↩︎
Ishizawa K, Dickson DW. Microglial activation parallels system degeneration in progressive supranuclear palsy and corticobasal degeneration. J Neuropathol Exp Neurol. 2001. ↩︎
Respondek G, Stamelou M, Höglinger GU. Current and future therapeutic approaches to PSP. Expert Rev Neurother. 2019. ↩︎ ↩︎
Kato N, Arai K, Hattori T. Study of the rostral midbrain atrophy in progressive supranuclear palsy. J Neurol Sci. 2003. ↩︎
Pirker W, Asenbaum S, Bencsits G, et al. 123I beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord. 2000. ↩︎
Whitwell JL, Lowe VJ, Tosakulwong N, et al. 18F Flortaucipir tau-PET in progressive supranuclear palsy. Mov Disord. 2017. ↩︎
Rojas JC, Bang J, Lobach IV, et al. CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology. 2018. ↩︎
Boxer AL, Qureshi I, Ahlijanian M, et al. Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial. Lancet Neurol. 2019. ↩︎
Tolosa E, Litvan I, Höglinger GU, et al. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord. 2014. ↩︎
Kaur et al. Single-cell transcriptomics of PSP substantia nigra (2024). 2024. ↩︎
Stanciu et al. Calcium dysregulation in tauopathy (2025). 2025. ↩︎
Vasili et al. Tau-alpha-synuclein cross-seeding in SN (2024). 2024. ↩︎
Matsumoto et al. Neuromelanin MRI in PSP diagnosis (2025). 2025. ↩︎
Hopper et al. Microglial PET in PSP progression (2024). 2024. ↩︎
Boxer et al. Neuroprotective therapies in PSP (2025). 2025. ↩︎